Table 5.

PCR evaluation of paired miRNA ratios in individual samples.

	Cancer vs. Benign∗ (53 vs. 40)	Cancer vs. Normal∗ (53 vs. 38)	Cancer vs. Control (Benign + Normal) (53 vs. 78)
Number of ratios that significantly identified with fold change > 1.5	28 (Table 2)	28 (Table 3)	21 (Table 4)
Number of ratios selected in the final model	5	4	5
Name of ratios selected in the final model	hsa-miR-30a-5p/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-574-5p, hsa-miR-21-3p/hsa-miR-221-3p, hsa-miR-221-3p/miR-30a-5p (Figure 1)	hsa-miR-324-3p/hsa-miR-382-5p, hsa-miR-21-3p/hsa-miR-324-3p, hsa-miR-30a-5p/has-miR-30e-5p, hsa-miR-221-3p/has-miR-324-3p (Figure 2)	hsa-miR-30e-5p/hsa-miR-382-5p, hsa-miR-221-3p/hsa-miR-324-3p, hsa-miR-30a-5p/hsa-miR-382-5p, hsa-miR-152/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-382-5p (Figure 3)
Sensitivity	0.881	0.890	0.717
Specificity	0.775	0.925	0.782
PPV	0.827	0.889	0.691
NPV	0.756	0.891	0.803
AUC	0.901	0.901	0.820

^∗Age as a co-founder was included in the model since it significantly differed between two groups. Sensitivity, specificity, PPV, NPV, and AUC were obtained from the final model after 10-fold cross-validation.